Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An Exposure-Response Perspective on the Clinical Dose of Pretomanid.
Nedelman JR, Salinger DH, Subramoney V, Woolson R, Wade K, Li M, Everitt D, Mendel CM, Spigelman M. Nedelman JR, et al. Among authors: mendel cm. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01121-20. doi: 10.1128/AAC.01121-20. Print 2020 Dec 16. Antimicrob Agents Chemother. 2020. PMID: 33077660 Free PMC article.
Daily Dosing for Bedaquiline in Patients with Tuberculosis.
Salinger DH, Nedelman JR, Mendel C, Spigelman M, Hermann DJ. Salinger DH, et al. Antimicrob Agents Chemother. 2019 Oct 22;63(11):e00463-19. doi: 10.1128/AAC.00463-19. Print 2019 Nov. Antimicrob Agents Chemother. 2019. PMID: 31451504 Free PMC article.
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.
Diacon AH, De Jager VR, Dawson R, Narunsky K, Vanker N, Burger DA, Everitt D, Pappas F, Nedelman J, Mendel CM. Diacon AH, et al. Among authors: mendel cm. Antimicrob Agents Chemother. 2020 Mar 24;64(4):e02012-19. doi: 10.1128/AAC.02012-19. Print 2020 Mar 24. Antimicrob Agents Chemother. 2020. PMID: 31988102 Free PMC article. Clinical Trial.
Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment".
Diacon AH, De Jager VR, Dawson R, Narunsky K, Vanker N, Burger DA, Everitt D, Pappas F, Nedelman J, Mendel CM. Diacon AH, et al. Among authors: mendel cm. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00709-20. doi: 10.1128/AAC.00709-20. Print 2020 Jun 23. Antimicrob Agents Chemother. 2020. PMID: 32366714 Free PMC article. No abstract available.
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
Oelofse S, Esmail A, Diacon AH, Conradie F, Olayanju O, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Wills GH, Olugbosi M, Del Parigi A, Sun E, Calatroni A, Spigelman M, Dheda K. Oelofse S, et al. Among authors: mendel cm. Int J Tuberc Lung Dis. 2021 Jun 1;25(6):453-460. doi: 10.5588/ijtld.21.0035. Int J Tuberc Lung Dis. 2021. PMID: 34049607 Free PMC article.
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, Samoilova A, Skornykova S, Tudor E, Variava E, Yablonskiy P, Everitt D, Wills GH, Sun E, Olugbosi M, Egizi E, Li M, Holsta A, Timm J, Bateson A, Crook AM, Fabiane SM, Hunt R, McHugh TD, Tweed CD, Foraida S, Mendel CM, Spigelman M; ZeNix Trial Team. Conradie F, et al. Among authors: mendel cm. N Engl J Med. 2022 Sep 1;387(9):810-823. doi: 10.1056/NEJMoa2119430. N Engl J Med. 2022. PMID: 36053506 Free PMC article. Clinical Trial.
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB.
Tweed CD, Wills GH, Crook AM, Amukoye E, Balanag V, Ban AYL, Bateson ALC, Betteridge MC, Brumskine W, Caoili J, Chaisson RE, Cevik M, Conradie F, Dawson R, Del Parigi A, Diacon A, Everitt DE, Fabiane SM, Hunt R, Ismail AI, Lalloo U, Lombard L, Louw C, Malahleha M, McHugh TD, Mendel CM, Mhimbira F, Moodliar RN, Nduba V, Nunn AJ, Sabi I, Sebe MA, Selepe RAP, Staples S, Swindells S, van Niekerk CH, Variava E, Spigelman M, Gillespie SH. Tweed CD, et al. Among authors: mendel cm. Int J Tuberc Lung Dis. 2021 Apr 1;25(4):305-314. doi: 10.5588/ijtld.20.0513. Int J Tuberc Lung Dis. 2021. PMID: 33762075 Free PMC article. Clinical Trial.
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. Dawson R, et al. Among authors: mendel cm. Lancet. 2015 May 2;385(9979):1738-1747. doi: 10.1016/S0140-6736(14)62002-X. Epub 2015 Mar 18. Lancet. 2015. PMID: 25795076 Clinical Trial.
84 results